Advanced Bionics appears in FDA device records as the applicant for P960058, a premarket approval for an implantable cochlear device. The same PMA number carries two trade names across the records: CLARION Multi-Strategy Cochlear Implant on the original approval and on a 2026 postapproval study protocol supplement, and HiResolution Bionic Ear System on a 2026 process-change supplement. FDA lists the generic name as Implant, cochlear, device class 3, product code MCM, with the Ear, Nose, Throat advisory committee. The filing address on these records is 28515 Westinghouse Pl., Valencia, CA 91355; that is a correspondence address in the filings, not a verified headquarters. No parent company, brand owner, website or commercial status is established by these records. [1][2][3]
The original pediatric approval
The earliest record in the set is the original P960058 approval, decided June 26, 1997, for the CLARION Multi-Strategy Cochlear Implant. The approval statement describes a device intended to restore a level of auditory sensation to children with deafness through electrical stimulation of the auditory nerve, and sets out pediatric indications tied to age, hearing aid trial and lack of aided benefit. A separate FDA approval memorandum dated June 1997 addresses premarket approval of the CLARION device for pediatric use. The 1997 notice also records that the CLARION cochlear implant was authorized to affix the CE mark in 1993, under an earlier Sylmar, CA address. [3][10]
2026 postapproval study protocol
Supplement S178, received August 21, 2026 and decided September 18, 2026, was approved under the trade name CLARION MULTI-STRATEGY COCHLEAR IMPLANT. FDA classifies it as a normal 180-day track supplement without user fee, with the reason given as postapproval study protocol. The applicant's statement in the record says the PAS protocol was submitted to comply with conditions of approval outlined in the approval order for P960058/S167. The supplement was not expedited and went to the Ear, Nose, Throat advisory committee. [1]
2026 manufacturing process change
Supplement S177, received August 7, 2026 and decided September 4, 2026, was approved under the trade name HiResolution Bionic Ear System. FDA records the supplement type as special immediate track and the reason as a process change involving manufacturer, sterilizer, packager or supplier. The approval statement describes the scope: removal of the non-tamperproof battery door in the external processor and its replacement with a validated tamperproof door in the packaged configuration of the M Zn-Air Battery Pak (CI-5501). The SSED for the earlier supplement S167, approved July 22, 2026, identifies the trade name as HiResolution Bionic Ear System, previously CLARION Multi-Strategy Cochlear Implant System, Model 1.2, and notes that the original PMA P940022 was approved March 22, 1996. FDA pages for P960058 and P960058/S167 note that a supplement may have changed the device description, function or indication from the original approval. [2][6][8]
What the collection shows
The linked collection holds three PMA records, all with an approved decision, and the smaller record sample of three also shows three approvals. These counts describe the retrieved filings as of November 20, 2026, not total company sales, total portfolio or safety performance. No recall records appear in the retrieved set. The documents establish an applicant identity, two trade names under one PMA number, and the stated scope of two 2026 supplements; they do not establish ownership, manufacturing sites beyond the named battery pak component, or clinical outcomes. [1][2][3]



